[CLSTR]
< Back to situation

[REVISION HISTORY]

Oura health technology company expansion and IPO

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-04 17:28 UTC → 2026-09-06 15:25 UTC · added removed

Finnish health technology company Oura is advancing toward a potential United States initial public offering (IPO) on the Nasdaq under the ticker OURA. Following a confidential filing, the company has filed an S-1 registration statement filing with the U.S. Securities and Exchange Commission. Oura has reported Commission, the company is seeking a valuation between $11 billion and $16 billion, with reports suggesting a potential capital raise of up to $3 billion. Financial filings reveal significant financial growth, with revenue reaching $1.21 billion for the nine months ending June 30, representing 30 reaching approximately $1.21 billion, a 74% increase over year-over-year. While hardware sales accounted for $974 million (80%) of revenue, subscription services are a rapidly growing segment, contributing $240.5 million. The company reported selling 3.6 million rings in the previous year. last 12 months and has grown its base to approximately 5 million paying subscribers. Net income for that the nine-month period rose to approximately $60.8 million, up from $1.6 million a year prior. Additionally, paid membership has grown to 5 million users, with membership revenue increasing 121% year-over-year. While the Despite this momentum, Oura faces several risks. The company has recently achieved profitability, the filing cautions noted that future profitability cannot be guaranteed and notes a history of operating losses. To support its scaling efforts, Oura has appointed Jason Warnick, Leslie Kilgore, Miki Kuusi, and David Sze to its board of directors. CEO Tom Hale stated these appointments aim to strengthen the board with leaders experienced battery performance issues in scaling global businesses. In terms of market expansion, the company launched the certain Oura Ring 4 units contributed to $84.4 million in India, a titanium smart ring priced between ₹28,900 and ₹39,900. However, the IPO filing identifies certain risks, including warranty expenses. Additionally, Oura faces a proposed class action class-action lawsuit regarding sleep tracking alleging it overstated the accuracy and warranty expenses related to battery defects in some Ring 4 units. Goldman Sachs of its sleep-tracking capabilities. Market competition is leading the underwriting syndicate, joined by Morgan Stanley, J.P. Morgan, Allen & Co., also intensifying. Competitors such as Ultrahuman are developing rings with advanced processors and Jefferies. Recent filings indicate Oura AI capabilities, while Circular is seeking a valuation that could reach between $11 billion working on models featuring NFC contactless payments and $16 billion, with reports suggesting a potential capital raise of up to $3 billion. The company FDA-cleared ECG functionality. Ultrahuman has also highlighted its competitive advantage through a massive biometric dataset containing 42 billion hours of physiological readings. recently navigated patent disputes involving Oura in the United States.

Versions

  1. 2026-09-06 15:25 UTC Oura health technology company expansion and IPO
  2. 2026-09-04 17:28 UTC Oura health technology company expansion and IPO
  3. 2026-09-04 01:15 UTC Oura health technology company expansion and IPO
  4. 2026-09-02 13:21 UTC Oura health technology company expansion and IPO

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.